Christopher Barry Wood

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Thirty Holdings Ltd. operates as a holding British company whose subsidiary develops an anti-infective nitric oxide technology platform for the healthcare sector. The company is based in London, UK. The company was founded in 2018 by Christopher Barry Wood.

MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom.

Thirty Holdings Ltd. operates as a holding British company whose subsidiary develops an anti-infective nitric oxide technology platform for the healthcare sector. The company is based in London, UK. The company was founded in 2018 by Christopher Barry Wood.

MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom.

Mina (Holdings) Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Mina (Holdings) Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments.

MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom.